BIO 2016 Notebook: Dealmaking, Reputation, Thailand And Boehringer Beyond Borders
During the final days of the BIO International Convention, we heard about trends in biopharma deals for 2016, a call to arms for individuals to do more to communicate the industry's positive impact, and anticipated reforms in Thailand.
You may also be interested in...
Big pharma investments in early innovation are paying off in ways that still are hard to measure in any concrete way, but green shoots are sprouting through the pavement as startups supported by multimillion-dollar initiatives evolve from concept to reality.
Scrip spoke with several executives and attended multiple panel discussions in San Francisco during the first full day of BIO's annual international gathering. Drug pricing and enabling innovation emerged as key themes.
Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.